“Penny Stock Aerpio Pharmaceuticals’ Merger With Aadi Makes It A Buy, Says Analyst”
July 9, 2021
“Aerpio Pharmaceuticals (ARPO) is a biopharmaceutical company focused on developing compounds that activate Tie2. Tie2 is considered a key regulator of vascular stability, and ARPO “believes that activation of Tie2 may have therapeutic potential” for different indications. In Q1, ARPO did not earn any revenues, but net loss widened to $4.4 million from $3.9 million in the same quarter a year ago. Aerpio’s operating expenses increased 36.7% year-over-year to $5.6 million in Q1. The company had cash and cash equivalents of $39 million as of March 31…
In May, Aerpio announced the merger with Aadi Bioscience. The merger is expected to close in the second half of this year. The completion of the merger will result in ARPO becoming a wholly-owned subsidiary of Aadi. Aadi Bioscience is a privately-held biopharmaceutical company focusing on precision therapies for genetically defined cancers with alterations in mTOR pathway genes…”
https://finance.yahoo.com/news/penny-stock-aerpio-pharmaceuticals-merger-113115565.html